"Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles"
Many viral and non-viral gene transfer systems suffer from common pharmacological issues that limit their utility in a systemic context. By application of the liposomal drug delivery paradigm, many of the limitations of the first generation non-viral delivery systems can be overcome. Encapsulation in small, long-circulating particles called stabilized plasmid lipid particles (SPLP) results in enhanced accumulation at disease sites and selective protein expression. This work compares the detergent dialysis method of SPLP manufacture with an alternative method, spontaneous vesicle formation by ethanol dilution. The pharmacology of SPLP, as determined by monitoring lipid label and quantitative real time PCR, is also presented.
Maclachlan
Ian
I
Protiva Biotherapeutics Incorporated, Burnaby, BC, Canada V5G 4Y1.
Cullis
Pieter
P